Which category of SGA is known for a high risk of weight gain and metabolic abnormalities?

The category of Second-Generation Antipsychotics (SGAs) associated with a high risk of weight gain and metabolic abnormalities includes certain medications that are particularly known for these side effects. SGA Pines refers to medications like clozapine and olanzapine, which are noted for their significant impact on metabolic parameters such as weight gain, dyslipidemia, and insulin resistance.

These drugs are effective in treating schizophrenia and bipolar disorder, but their propensity to cause weight gain is a considerable clinical concern. The mechanism of weight gain associated with these antipsychotics may involve increased appetite and changes in metabolism, making patients more vulnerable to metabolic syndrome.

Understanding this category's side effect profile is critical for managing patients' overall health, particularly in psychiatric settings where long-term medication management is common. Factors influencing patient adherence to medication regimens may also stem from concerns regarding weight gain and metabolic issues, highlighting the importance of monitoring these effects during treatment.